Gilead Sciences Reports Phase 3 ZUMA-7 Results for Yescarta in Second-Line DLBCL
Biotechnology Media Insights
Editorial Team · September 12, 2023
Gilead Sciences announces Phase 3 ZUMA-7 trial results showing Yescarta CAR-T therapy significantly improves event-free survival vs standard of care in second-line DLBCL.
Gilead Sciences today announced results from the Phase 3 ZUMA-7 trial evaluating Yescarta (axicabtagene ciloleucel) versus standard of care in patients with relapsed or refractory large B-cell lymphoma who were candidates for autologous stem cell transplantation. The trial met its primary endpoint, demonstrating a significant improvement in event-free survival with Yescarta.
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.